Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats

Bone

Volumn 66, Issue , 2014, Pages 287-295

  Vegger, Jens Bay ^a   Nielsen, Esben Sommer ^a   Brüel, Annemarie ^a   Thomsen, Jesper Skovhus ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomechanics; Bisphosphonate; Histomorphometry; Immobilization; MicroCT; PTH

Indexed keywords

BOTULINUM TOXIN A; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE ATROPHY; BONE DEVELOPMENT; BONE MASS; BONE STRENGTH; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; IMMOBILIZATION; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOPENIA; PERIOSTEUM; RAT; RAT MODEL; TIBIA; TRABECULAR BONE; DIAPHYSIS; DRUG RESPONSE; GAIT; GASTROCNEMIUS MUSCLE; METAPHYSIS; MUSCLE MASS; OSTEOLYSIS; ANIMAL; BONE; BONE DISEASES, METABOLIC; DRUG EFFECTS; DRUG POTENTIATION; MUSCULAR DISORDERS, ATROPHIC; PATHOLOGY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; THREE DIMENSIONAL IMAGING; WISTAR RAT;

ABSORPTIOMETRY, PHOTON; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DISEASES, METABOLIC; DIPHOSPHONATES; DRUG SYNERGISM; FEMALE; IMAGING, THREE-DIMENSIONAL; IMIDAZOLES; MUSCULAR DISORDERS, ATROPHIC; PARATHYROID HORMONE; RATS, WISTAR; X-RAY MICROTOMOGRAPHY;

EID: 84904266031     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.020     Document Type: Article

References (60)

1. Thomsen J.S., Morukov B.V., Vico L., Alexandre C., Saparin P.I., Gowin W. Cancellous bone structure of iliac crest biopsies following 370days of head-down bed rest. Aviat Space Environ Med 2005, 76:915-922.
2. Chappard D., Alexandre C., Palle S., Vico L., Morukov B.V., Rodionova S.S., et al. Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. Metabolism 1989, 38:822-825.
3. Krølner B., Toft B. Vertebral bone loss: an unheeded side effect of therapeutic bed rest. Clin Sci (Lond) 1983, 64:537-540.
4. Ebbesen E.N., Thomsen J.S., Beck-Nielsen H., Nepper-Rasmussen H.J., Mosekilde L. Age- and gender-related differences in vertebral bone mass, density, and strength. J Bone Miner Res 1999, 14:1394-1403.
5. Vico L., Chappard D., Alexandre C., Palle S., Minaire P., Riffat G., et al. Effects of a 120day period of bed-rest on bone mass and bone cell activities in man: attempts at countermeasure. Bone Miner 1987, 2:383-394.
6. Spector E.R., Smith S.M., Sibonga J.D. Skeletal effects of long-duration head-down bed rest. Aviat Space Environ Med 2009, 80:A23-A28.
7. Pavy-Le Traon A., Heer M., Narici M.V., Rittweger J., Vernikos J. From space to Earth: advances in human physiology from 20years of bed rest studies (1986-2006) 2007.
8. Tian X., Jee W.S.S., Li X., Paszty C., Ke H.Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011, 48:197-201.
9. Zeng Q.Q., Jee W.S., Bigornia A.E., King J.G., D'Souza S.M., Li X.J., et al. Time responses of cancellous and cortical bones to sciatic neurectomy in growing female rats. Bone 1996, 19:13-21.
10. Morey E.R., Sabelman E.E., Turner R.T., Baylink D.J. A new rat model simulating some aspects of space flight. Physiologist 1979, 22:S23-S24.
11. Allison N., Brooks B. Bone atrophy: an experimental and clinical study of the changes in bone which result from non-use. Surg Gynecol Obstet 1921, 33:250-260.
12. Akamine T., Jee W.S., Ke H.Z., Li X.J., Lin B.Y. Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in female rats. Bone 1992, 13:11-22.
13. Chappard D., Chennebault A., Moreau M., Legrand E., Audran M., Basle M.F. Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the Clostridium botulinum toxin. Bone 2001, 28:72-79.
14. Breidenbach M.A., Brunger A.T. New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med 2005, 11:377-381.
15. Brunger A.T., Jin R., Breidenbach M.A. Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell Mol Life Sci 2008, 65:2296-2306.
16. Thomsen J.S., Christensen L.L., Vegger J.B., Nyengaard J.R., Brüel A. Loss of bone strength is dependent on skeletal site in disuse osteoporosis in rats. Calcif Tissue Int 2012, 90:294-306.
17. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
18. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
19. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40:1434-1446.
20. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
21. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136:3632-3638.
22. Kim S.W., Pajevic P.D., Selig M., Barry K.J., Yang J.-Y., Shin C.S., et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 2012, 27:2075-2084.
23. Aslan D., Andersen M.D., Gede L.B., de Franca T.K., Jørgensen S.R., Schwarz P., et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 2012, 72:14-22.
24. Gasser J.A., Kneissel M., Thomsen J.S., Mosekilde L. PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 2000, 1:53-56.
25. Yang X., Chan Y.H., Muthukumaran P., Dasde S., Teoh S.-H., Lee T. Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study. Bone 2011, 48:1154-1163.
26. Li M., Mosekilde L., Søgaard C.H., Thomsen J.S., Wronski T.J. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995, 16:629-635.
27. Wu X., Pang L., Lei W., Lu W., Li J., Li Z., et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010, 7:571-580.
28. Yamane H., Sakai A., Mori T., Tanaka S., Moridera K., Nakamura T. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 2009, 44:1055-1062.
29. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
30. Finkelstein J.S., Wyland J.J., Lee H., Neer R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010, 95:1838-1845.
31. Cosman F., Eriksen E.F., Recknor C., Miller P.D., Guañabens N., Kasperk C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
32. Warner S.E., Sanford D.A., Becker B.A., Bain S.D., Srinivasan S., Gross T.S. Botox induced muscle paralysis rapidly degrades bone. Bone 2006, 38:257-264.
33. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
34. Thomsen J.S., Laib A., Koller B., Prohaska S., Mosekilde L., Gowin W. Stereological measures of trabecular bone structure: comparison of 3D micro computed tomography with 2D histological sections in human proximal tibial bone biopsies. J Microsc 2005, 218:171-179.
35. Brüel A., Vegger J.B., Raffalt A.C., Andersen J.E.T., Thomsen J.S. PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats. Bone 2013, 53:51-58.
36. Ma Y.F., Jee W.S., Ke H.Z., Lin B.Y., Liang X.G., Li M., et al. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J Bone Miner Res 1995, 10:496-505.
37. Turner R.T., Evans G.L., Lotinun S., Lapke P.D., Iwaniec U.T., Morey-holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 2007, 22:64-71.
38. Gordon K.E., Wald M.J., Schnitzer T.J. Effect of parathyroid hormone combined with gait training on bone density and bone architecture in people with chronic spinal cord injury. PM R 2013, 5:663-671.
39. Ma Y.L., Zeng Q.Q., Porras L.L., Harvey A., Moore T.L., Shelbourn T.L., et al. Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 2011, 152:1767-1778.
40. Silvestrini G., Ballanti P., Leopizzi M., Sebastiani M., Berni S., Di Vito M., et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007, 38:261-269.
41. Moriyama I., Iwamoto J., Takeda T., Toyama Y. Comparative effects of intermittent administration of human parathyroid hormone (1-34) on cancellous and cortical bone loss in tail-suspended and sciatic neurectomized young rats. J Orthop Sci 2002, 7:379-385.
42. Turner R.T., Evans G.L., Cavolina J.M., Halloran B., Morey-Holton E. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 1998, 139:4086-4091.
43. Li X., Liu H., Qin L., Tamasi J., Bergenstock M., Shapses S., et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007, 282:33086-33097.
44. Perilli E., Le V., Ma B., Salmon P., Reynolds K., Fazzalari N.L. Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporos Int 2010, 21:1371-1382.
45. Yao W., Cheng Z., Koester K.J., Ager J.W., Balooch M., Pham A., et al. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. Bone 2007, 41:804-812.
46. Brouwers J.E.M., van Rietbergen B., Bouxsein M.L. Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats. Calcif Tissue Int 2008, 83:186-191.
47. Lloyd S.A.J., Travis N.D., Lu T., Bateman T.A. Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse. J Appl Physiol 2008, 104:729-738.
48. Bubbear J.S., Gall A., Middleton F.R.I., Ferguson-Pell M., Swaminathan R., Keen R.W. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int 2011, 22:271-279.
49. Shapiro J., Smith B., Beck T., Ballard P., Dapthary M., BrintzenhofeSzoc K., et al. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int 2007, 80:316-322.
50. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
51. Mosekilde L. Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study (uncoupling of unloaded structures). Bone Miner 1990, 10:13-35.
52. Altman A.R., Tseng W.-J., de Bakker C.M.J., Huh B.K., Chandra A., Qin L., et al. A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone 2014, 61:149-157.
53. Yang X., Muthukumaran P., DasDe S., Teoh S.H., Choi H., Lim S.-K., et al. Positive alterations of viscoelastic and geometric properties in ovariectomized rat femurs with concurrent administration of ibandronate and PTH. Bone 2013, 52:308-317.
54. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
55. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?. Bone 1995, 16:603-610.
56. Yao W., Su M., Zhang Q., Tian X., Setterberg R.B., Blanton C., et al. Risedronate did not block the maximal anabolic effect of PTH in aged rats. Bone 2007, 41:813-819.
57. Turek J., Ebetino F.H., Lundy M.W., Sun S., Kashemirov B.A., McKenna C.E., et al. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif Tissue Int 2012, 90:202-210.
58. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16:2950-2960.
59. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21:366-373.
60. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.